Close

Ms Katherine Gallagher

Associate Professor

United Kingdom

I am an epidemiologist trained in infectious disease epidemiology and vaccine research with experience of pre-licensure, post-licensure vaccine trials and post-introduction surveillance and evaluation projects.

My PhD research documented best practice in the introduction of Human Papillomavirus (HPV) vaccine delivery in 46 low- and middle-income countries and included a post-introduction evaluation study in Tanzania. During this time, I was based at the Mwanza Intervention Trials Unit for 2 years and aided the rapid set up of a Phase 1 Ebola Vaccine trial during the West African epidemic. My first post-doc position was as a london-based coordinator of the larger EBOVAC project at LSHTM, which included two different phase 2 vaccine trials in Sierra Leone of the two-dose Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen.

Since July 2018, I have been based at the KEMRI-Wellcome Trust Research Programme in Kenya leading a phase 4 trial assessing whether fractional doses of Pneumococcal Conjugate Vaccines (PCV) elicit non-inferior immunogenicity and effects on carriage as full doses. During the COVID-19 pandemic I led some of the serosurveillance for SARS-CoV-2 in Kenya and contributed to a household study of SARS-CoV-2 transmission. In collaboration with partners at the UVRI/MRC & LSHTM unit in Uganda, COMAHS in Sierra Leone and INRB in DRC, we obtained funding to conduct a mixed-methods evaluation of how the COVID-19 pandemic affected utilisation and provision of childhood vaccinations and other primary healthcare services in the three countries and we conducted longitudinal serosurveillance for SARS-CoV-2 among healthcare workers.

I currently supervise two PhD students who are assessing the relationship between PCV coverage and carriage, and the relationship between carriage and invasive pneumococcal disease in Ethiopia and DRC. I continue to be interested in improving our understanding of transmission of infectious diseases and our measurement of host susceptibility , in order to develop and use vaccines more effectively to control transmission and disease.

Affiliations

Department of Infectious Disease Epidemiology and International Health
Faculty of Epidemiology and Population Health

Centres

Centre for Epidemic Preparedness and Response

Teaching

I am a Fellow of the Advance Higher Education Academy (FHEA, Advance HE UK). I am a module co-organiser for the LSHTM Distance Learning MSc module: Epidemiological Study Design. I tutor on the LSHTM Distance Learning Epidemiology and Control of Communicable Disease Module. I lecture and tutor on the face-to-face MSc module ‘Design and Analysis of Epidemiological Studies’ and the short course: Epidemiological evaluation of vaccines: efficacy, safety and policy.

Research

High-quality epidemiological research to inform vaccine policy
Research Area
Adolescent health
Bacteria
Child health
Clinical trials
Evaluation
Immunisation
Public health
Vaccines
Epidemiology
Vaccinology
Virology
Disease and Health Conditions
Human papillomavirus (HPV)
Emerging infectious diseases
Respiratory diseases
Country
Kenya
Sierra Leone
Somalia
Tanzania

Selected Publications

The Predictive Performance of a Pneumonia Severity Score in Human Immunodeficiency Virus-negative Children Presenting to Hospital in 7 Low- and Middle-income Countries.
GALLAGHER, KE; Knoll, MD; Prosperi, C; Baggett, HC; Brooks, WA; Feikin, DR; Hammitt, LL; Howie, SR C; Kotloff, KL; Levine, OS; Madhi, SA; Murdoch, DR; O'Brien, KL; Thea, DM; Awori, JO; Baillie, VL; Ebruke, BE; Goswami, D; Kamau, A; Maloney, SA; Moore, DP; Mwananyanda, L; Olutunde, EO; Seidenberg, P; Sissoko, S; ... SCOTT, JA G.
2019
Clinical Infectious Diseases
Status of HPV vaccine introduction and barriers to country uptake.
GALLAGHER, KE; LaMontagne, DS; WATSON-JONES, D;
2018
Vaccine
Lessons learnt from human papillomavirus (HPV) vaccination in 45 low- and middle-income countries.
GALLAGHER, KE; HOWARD, N; Kabakama, S; MOUNIER-JACK, S; Griffiths, UK; Feletto, M; BURCHETT, HE D; LaMontagne, DS; WATSON-JONES, D;
2017
PloS one
The value of demonstration projects for new interventions: The case of human papillomavirus vaccine introduction in low- and middle-income countries.
HOWARD, N; MOUNIER-JACK, S; GALLAGHER, KE; Kabakama, S; GRIFFITHS, UK; Feletto, M; LaMontagne, DS; BURCHETT, HE D; WATSON-JONES, D;
2016
Human vaccines & immunotherapeutics
The Association Between Cervical Human Papillomavirus Infection and Subsequent HIV Acquisition in Tanzanian and Ugandan Women: A Nested Case-Control Study.
GALLAGHER, KE; BAISLEY, K; GROSSKURTH, H; Vallely, A; KAPIGA, S; Vandepitte, J; Kamali, A; De Sanjosé, S; Changalucha, J; HAYES, R; WATSON-JONES, D;
2016
The Journal of infectious diseases
Factors influencing completion of multi-dose vaccine schedules in adolescents: a systematic review.
GALLAGHER, KE; Kadokura, E; Eckert, LO; Miyake, S; MOUNIER-JACK, S; Aldea, M; ROSS, DA; WATSON-JONES, D;
2016
BMC public health
Lessons learnt from human papillomavirus (HPV) vaccine demonstration projects and national programmes in low- and middle-income countries
GALLAGHER, KE; Kabakama, S; HOWARD, N; MOUNIER-JACK, S; GRIFFITHS, UK; Feletto, M; Lamontagne, DS; BURCHETT, HE D; WATSON-JONES, D;
2016
Factors predicting mortality in hospitalised HIV-negative children with lower-chest-wall indrawing pneumonia and implications for management.
GALLAGHER, KE; Awori, JO; Knoll, MD; Rhodes, J; Higdon, MM; Hammitt, LL; Prosperi, C; Baggett, HC; Brooks, WA; Fancourt, N; Feikin, DR; Howie, SR C; Kotloff, KL; Tapia, MD; Levine, OS; Madhi, SA; Murdoch, DR; O'Brien, KL; Thea, DM; Baillie, VL; Ebruke, BE; Kamau, A; Moore, DP; Mwananyanda, L; Olutunde, EO; ... PERCH Study Group,
2024
PloS one
Evaluation of statistical models of carriage to predict the impact of the 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in Nigeria
ADAMU, AL; Ojal, J; MBURU, C; GALLAGHER, KE; FLASCHE, S; Odeyemi, K; Okoromah, CA N; Abubakar, IS; Bello, MM; Inem, V; Karani, A; Karia, B; Akech, D; Adetifa, IM O; Scott, JA G;
2024
Cold Spring Harbor Laboratory
See more information